Suvorexant


Catalog No. Size PriceQuantity
M6591-2S CUSTOMER ORDER $7,000

Description

Suvorexant, also known as MK-4305, is a discontinued (DEA controlled substance) biochemical.

Product information

CAS Number: 1030377-33-3

Molecular Weight: 450.92

Formula: C23H23ClN6O2

Synonym:

MK4305

MK 4305

MK-4305

Chemical Name: (R)-(4-(5-chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.

Smiles: CC1C=C(C(=CC=1)N1N=CC=N1)C(=O)N1CCN(CC[C@H]1C)C1=NC2=CC(Cl)=CC=C2O1

InChiKey: JYTNQNCOQXFQPK-MRXNPFEDSA-N

InChi: InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1

Technical Data

Appearance: white to off-white solid powder

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

References:

  1. McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des. 2014 Jan;28(1):5-12. doi: 10.1007/s10822-014-9710-x. Epub 2014 Feb 1. PubMed PMID: 24488306; PubMed Central PMCID: PMC3927067.
  2. Strotman NA, Baxter CA, Brands KM, Cleator E, Krska SW, Reamer RA, Wallace DJ, Wright TJ. Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual Orexin inhibitor Suvorexant (MK-4305). J Am Chem Soc. 2011 Jun 1;133(21):8362-71. doi: 10.1021/ja202358f. Epub 2011 May 11. PubMed PMID: 21528938.
  3. Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28. PubMed PMID: 23197752.
  4. Hopkins CR. ACS chemical neuroscience molecule spotlight on Suvorexant. ACS Chem Neurosci. 2012 Sep 19;3(9):647-8. Review. PubMed PMID: 23024835; PubMed Central PMCID: PMC3447389.

Products are for research use only. Not for human use.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard PayPal Shop Pay Venmo Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like

Recently viewed